Formulation and physical characterization of large porous particles for inhalation

Pharmaceutical Research

Volumn 16, Issue 11, 1999, Pages 1735-1742

  Vanbever, Rita ^a,b,c   Mintzes, Jeffrey D ^b,d   Wang, Jue ^b   Nice, Jacquelyn ^b,d   Chen, Donghao ^b,d   Batycky, Richard ^d   Langer, Robert ^a   Edwards, David A ^b,d  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b The Pennsylvania State University   (United States)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d Advanced Inhalation Research Inc   (United States)

Author keywords

Aerosolization properties; Dry powder; Excipients; Large porous particles; Pulmonary drug delivery

Indexed keywords

DIPALMITOYLPHOSPHATIDYLCHOLINE; ESTRADIOL; EXCIPIENT; HUMAN INSULIN; HUMAN SERUM ALBUMIN; LACTOSE; LUNG SURFACTANT; SALBUTAMOL;

AEROSOL; ARTICLE; DEVICE; DRUG FORMULATION; DRY POWDER; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; AEROSOLS; CHEMISTRY, PHARMACEUTICAL; DENSITOMETRY; EXCIPIENTS; MODELS, CHEMICAL; PARTICLE SIZE; POROSITY; SURFACE-ACTIVE AGENTS;

EID: 0032734092     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018910200420     Document Type: Article

References (26)

1. 1. A. J. Hickey (ed.). Inhalation aerosols - Physical and biological basis for therapy, in Lung Biology in Health and Disease, C. Lenfant (ex. ed.) 94, 1996.
2. 2. M. P. Timsina, G. P. Martin, C. Marriot, D. Ganderton, and M. Yianneskis. Drug delivery to the respiratory tract using dry powders inhalers. Int. J. Pharm. 101:1-13 (1994).
3. 3. D. L. French, D. A. Edwards, and R. W. Niven. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J. Aerosol Sci. 27:769-783 (1996).
4. 4. W.-I. Li, M. Perzl, J. Heyder, R. Langer, J. D. Brain, K.-H. Englmeier, R. W. Niven, and D. A. Edwards. Aerodynamics and aerosol particle deaggregation phenomena in model oral-pharyngeal cavities. J. Aerosol Sci. 27:1269-1286 (1996).
5. 5. D. A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M. L. Eskew, J. D. Mintzes, D. Deaver, N. Lotan, and R. Langer. Large porous particles for pulmonary drug delivery. Science 276:1868-1871 (1997).
6. 6. A. Ben-Jebria, D. Chen, M.-L. Eskew, R. Vanbever, R. Langer, and D. A. Edwards. Inhalation of large porous albuterol particles for sustained bronchodilation. Pharm. Res. 16:555-561 (1999).
7. 7. J. Wang, A. Ben-Jebria, and D. A. Edwards. Inhalation of estradiol for sustained systemic delivery J. Aerosol Med. 12:27-32 (1999).
8. 8. R. Vanbever, A. Ben-Jebria, J. D. Mintzes, R. Langer, and D. A. Edwards. Sustained-release of insulin from insoluble inhaled particles. Intern. Symp. Control. Rel. Bioact. Mater. 25:261-262 (1998).
9. rd edition, addendum 1999, 74-77.
10. 10. I. Gonda. Topics in Pharmaceutical Sciences 1991, D. J. A. Crommelin and K. K. Midha (eds), Medpharm Scientific, Stuttgart, 1992.
11. 11. H. Brenner and D. A. Edwards, Macrotransport Processes, Butterworth-Heinemann, 1993.
12. 12. K. Masters Spray drying handbook (5th. ed.), Longman Scientific and Technical, 1991.
13. 13. M. Sacchetti and M. M. Van Oort. Spray-drying and supercritical fluid particle generation techniques. In: A. J. Hickey (ed), Inhalation Aerosols, Marcel Dekker, 1996, 337-384.
14. 14. J. D. Andya, Y.-F. Maa, H. R. Costantino, P.-A. Nguyen, N. Dasovich, T. D. Sweeney, C. C. Hsu, and S. J. Shire. The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm. Res. 16:350-358 (1999).
15. 15. A. R. Clark and M. Egan. Modelling and deposition of inhaled powders drug aerosols. J. Aerosols Sci. 25:175-186 (1994).
16. 16. E. Mathiowitz, H. Bernstein, S. Giannos, P. Dor, T. Turek, and R. Langer. Polyanhydride microspheres. IV. Morphology and characterization of systems made by spray drying, J. Appl. Poly. Sci. 45:125-134 (1992).
17. 17. Y.-F. Maa, P.-A. Nguyen, and S. W. Hsu. Spray drying of air-liquid interface sensitive recombinant human growth hormone. J. Pharm. Sci. 87:152-159 (1998).
18. 18. X. M. Zeng, G. P. Martin, and C. Marriot. Albumin microspheres as a means of drug delivery to the lung: analysis of the effects of process variables on particle sizes using factorial design methodology. Int. J. Pharm. 107:205-210 (1994).
19. 19. X. M. Zeng, G. P. Martin, and C. Marriot. Tetrandrine delivery to the lung: The optimisation of albumin microspheres preparation by central composite design, Int. J. Pharm. 109:135-145 (1994).
20. 20. J. A. Clements and R. J. King. Composition of the surface active material. In: R. G. Crystal (ed.), The Biochemical Basis of Pulmonary Function, Marcel Dekker, Inc, 1976, chap 10.
21. 21. S. I. Rennard, G. Basset, D. Lecossier, K. M. O'Donnell, P. Pinkston, P. G. Martin, and R. G. Crystal. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. 60:532-538 (1986).
22. 22. N. J. Toremalm. The daily amount of tracheo-bronchial secretions in man. Acta Oto-laryng. (suppl.) 158:43-53 (1960).
23. 23. J. S. Patton. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Del Rev. 19:3-36 (1996).
24. 24. E. R. Weibel. Morphometry of the Human Lung, New York Academic Press, 1963.
25. 25. R. J. Mason and M. C. Williams. Alveolar type II cells. In: R. G. Crystal, J. R. West et al (eds), The lung: scientific foundations, New York Raven Press Ltd, 1991, Chap. 3.1.9.
26. 26. G. Scheuch, T. Meyer, K. Sommerer, H. Lichte, A. Pohner, W. Hess, P. Brand, G. Caponetti, K. Haussinger, J. Heyder, R. Batycky, R. Niven, and D. A. Edwards. Measuring in vivo deposition of large porous particles. Presented at the Biannual ISAM Meeting, Vienna, June 12-16, 1999).